As of 2026, no completed randomised controlled trial has evaluated emideltide — the synthetic analogue of delta sleep-inducing peptide (DSIP) — in insomnia, narcolepsy, or opioid use disorder. The available human record consists of small uncontrolled Soviet-era infusion studies and one opioid withdrawal series. Regulators have explicitly cited this evidence gap as the central barrier to any compounding pathway.
What Is Emideltide and How Does It Differ From Endogenous DSIP?
Emideltide is the INN-designated synthetic nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — a sequence-identical analogue of delta sleep-inducing peptide (DSIP), first isolated from rabbit thalamic venous blood by Monnier and colleagues in 1977. Emideltide refers specifically to the manufactured pharmaceutical-grade form intended for exogenous administration, distinct from endogenous DSIP subject to rapid enzymatic degradation.
DSIP was originally characterised by its ability to induce high-voltage delta-wave sleep activity when infused into the thalamus of rabbits. Monnier's group demonstrated that dialysate from the thalamic venous blood of electrically stimulated rabbits could transfer a sleep state to recipient animals — an observation that launched three decades of investigation into the peptide's somnogenic properties. The nine-amino-acid sequence was confirmed by Schoenenberger and colleagues in 1978.
Emideltide's proposed mechanisms include modulation of hypothalamic-pituitary-adrenal (HPA) axis activity, attenuation of corticotropin-releasing hormone (CRH) release, and interaction with opioid receptor systems — the last of which forms the mechanistic basis for its investigation in opioid use disorder. Whether any of these mechanisms operates at pharmacologically achievable concentrations following exogenous administration in humans remains unresolved.
The peptide is rapidly degraded by serum peptidases, with a plasma half-life estimated at under 10 minutes in rodent models. This pharmacokinetic liability has complicated all human administration attempts and means that the biologically active fraction reaching central targets after peripheral injection is unknown. No human pharmacokinetic study using validated bioanalytical methods has been published.
What Human Evidence Exists for Emideltide in Insomnia?
The insomnia evidence for emideltide consists of small open-label infusion studies from the 1980s and 1990s. The most cited series — Schoenenberger et al. (1984) — reported subjective sleep improvement in 9 of 12 patients with chronic insomnia following intravenous DSIP infusion, but lacked a placebo arm, blinding, or polysomnographic validation. No controlled trial has been registered or completed.
Schoenenberger's 1984 open series administered DSIP intravenously at doses ranging from 25 to 30 nanomoles per kilogram over 20 minutes in patients with chronic insomnia of varying aetiology. Patients reported improved sleep onset and reduced nocturnal awakenings over a two-week follow-up period. No objective sleep architecture data — polysomnography, actigraphy, or EEG staging — were reported alongside the subjective outcomes.
A subsequent series by Graf and colleagues (1985) in Switzerland examined DSIP infusion in 20 patients with psychophysiological insomnia and reported statistically significant reductions in sleep latency and wake-after-sleep-onset time by patient diary. No blinded control condition was employed. The authors acknowledged that expectation effects and the clinical attention associated with intravenous infusion protocols could not be excluded as confounders.
The FDA's evaluation framework for insomnia therapeutics requires at minimum two adequate and well-controlled trials demonstrating statistically significant improvements on polysomnographic endpoints. The emideltide literature does not approach this bar. The existing open-label series are methodologically insufficient to establish efficacy under current regulatory standards, and no IND-supported trial has been registered in ClinicalTrials.gov as of 2026.
Is There Any Human Evidence for Emideltide in Narcolepsy?
Human evidence for emideltide in narcolepsy is essentially absent. No clinical trial — controlled or uncontrolled — has specifically enrolled narcolepsy patients and evaluated emideltide against the condition's defining features: excessive daytime sleepiness, cataplexy, sleep paralysis, or hypnagogic hallucinations. The mechanistic rationale for its use in narcolepsy is indirect and untested in humans or orexin-deficient animal models.
The theoretical basis for investigating DSIP in narcolepsy rests on its proposed role in modulating sleep-wake transitions and HPA axis tone. Narcolepsy type 1 is characterised by orexin/hypocretin neuron loss in the lateral hypothalamus; DSIP's hypothalamic activity has been proposed as a potential compensatory modulator, but this hypothesis has never been tested in orexin-deficient animal models, let alone in human narcolepsy populations.
A small number of case reports from Eastern European literature in the 1990s described DSIP administration in patients with hypersomnia syndromes, but these reports did not apply modern narcolepsy diagnostic criteria (ICSD-3), did not measure CSF orexin levels, and did not use validated daytime sleepiness instruments such as the Epworth Sleepiness Scale or the Multiple Sleep Latency Test. Their evidentiary weight is negligible by current standards.
The mechanistic disconnect is significant: narcolepsy type 1 is a hypocretin-deficiency disorder, and no published data — preclinical or clinical — demonstrate that emideltide upregulates orexin signalling or compensates for hypocretin neuron loss. Practitioners should not extrapolate emideltide's putative somnogenic properties in normal sleep to a disorder defined by a specific neurotransmitter deficit.
What Is the Human Evidence for Emideltide in Opioid Use Disorder?
The opioid use disorder evidence base is the most developed of the three indications — but remains methodologically weak. The most substantive human data come from Soviet and Russian studies conducted between 1985 and 1998, examining DSIP infusion as an adjunct to opioid withdrawal management. These studies reported reduced withdrawal severity but were uniformly uncontrolled and used non-standardised outcome instruments.
Sudakov and colleagues published a series of reports between 1989 and 1995 describing DSIP administration in patients undergoing opioid detoxification. The most frequently cited study enrolled 40 patients with heroin dependence and reported that intravenous DSIP infusion over five days significantly attenuated scores on a non-validated Russian-language withdrawal symptom checklist compared to historical controls. No concurrent placebo group was enrolled, and the historical control comparison is methodologically unreliable.
The mechanistic rationale for DSIP in opioid withdrawal is better developed than for the sleep indications. DSIP has been shown in rodent models to interact with mu-opioid receptors, attenuate naloxone-precipitated withdrawal in morphine-dependent animals, and modulate CRH release — a key driver of the hyperarousal and dysphoria characteristic of opioid withdrawal syndrome. These preclinical findings provide a plausible biological basis for the clinical hypothesis, but do not substitute for controlled human evidence.
A 1998 study by Kopytov and colleagues — the most methodologically detailed in the Russian literature — enrolled 28 patients with opioid dependence and administered DSIP intravenously at 30 nanomoles per kilogram daily for seven days alongside standard supportive care. Withdrawal severity scores were reported to decrease more rapidly than in a historical comparison group. The study lacked randomisation, allocation concealment, and blinding, and no pharmacokinetic measurements were taken.
What Has Regulatory Review Concluded About Emideltide's Evidence Base in 2026?
Regulatory bodies reviewing emideltide for compounding eligibility have consistently concluded that the compound lacks adequate human safety and efficacy data across all proposed indications. The FDA's evaluation identified absent human pharmacokinetic data, no IND-supported clinical trial, and methodological deficiencies in the open-label literature as the primary barriers to a positive compounding determination under the 503A bulk drug substances framework.
Emideltide has been nominated for inclusion on the FDA's 503A bulk drug substances list — the pathway that would permit licensed compounding pharmacies to prepare it for patient-specific prescriptions. The FDA's preliminary assessment has focused on three evidentiary requirements: human pharmacokinetic characterisation, at least one controlled efficacy study, and a formal safety assessment including immunogenicity evaluation for injectable preparations.
None of these three requirements has been met as of 2026. The existing literature does not include a single study with validated bioanalytical measurement of emideltide plasma concentrations in humans, a placebo-controlled efficacy trial in any indication, or a systematic immunogenicity assessment. The regulatory position is therefore not a judgment that emideltide is unsafe — it is a determination that the evidence base is insufficient to make any safety or efficacy determination.
This evidentiary posture is consistent with the FDA's July 2026 PCAC approach to other peptides reviewed in the same cycle. As documented in the committee's review of BPC-157, TB-500, KPV, and MOTS-c, absent human pharmacokinetic data and the lack of any approved indication are treated as disqualifying gaps when evaluating compounding eligibility under the Drug Quality and Security Act framework.
What Pharmacokinetic Data Are Missing and Why Do They Matter for Protocol Design?
The pharmacokinetic record for emideltide in humans is essentially blank. No published study has characterised its absorption, distribution, metabolism, or elimination profile in human subjects using validated bioanalytical methods. Without human PK data, establishing a rational dose, dosing interval, or route of administration is impossible — making any current protocol an empirical extrapolation from rodent data and uncontrolled infusion series.
Emideltide's rapid degradation by serum peptidases — with a plasma half-life estimated at under 10 minutes in rodent models — raises a fundamental question about whether peripheral intravenous administration achieves any meaningful central nervous system exposure. The blood-brain barrier penetration of intact DSIP is disputed in the literature: some rodent studies report central effects after peripheral administration, while others suggest that observed effects may be mediated by peripheral receptors or by degradation fragments with independent activity.
The route-of-administration question is unresolved for all proposed indications. The historical human studies used intravenous infusion exclusively. Subcutaneous administration — the most practical route for outpatient protocols — has not been evaluated in humans. Intranasal delivery, which bypasses first-pass degradation and may improve CNS access, has been proposed in preclinical literature but has no human pharmacokinetic data to support it.
Without established human PK parameters, any dosing protocol for emideltide is extrapolated from rodent data and uncontrolled human infusion series. The doses used in historical human studies — typically 25 to 30 nanomoles per kilogram intravenously — were selected empirically rather than derived from pharmacokinetic modelling. Practitioners designing protocols in the absence of this foundational data are operating without a rational dose-response framework.
What Is the Known Safety Profile of Emideltide in Human Studies?
Safety data for emideltide in humans are sparse and derived exclusively from the same small, uncontrolled series that constitute the efficacy record. No serious adverse events were reported in the published open-label literature, but the studies were too small and methodologically limited to characterise the safety profile with confidence. Immunogenicity, endotoxin contamination risk, and long-term safety remain entirely uncharacterised.
The historical infusion studies reported no serious adverse events and described the compound as well-tolerated at doses of 25 to 30 nanomoles per kilogram intravenously. Mild transient effects — including brief sedation, mild hypotension, and occasional nausea — were noted in some participants. These observations were not systematically collected or graded using standardised adverse event criteria.
Immunogenicity has not been assessed in any published human study. For a nonapeptide administered by injection, the immunogenic potential depends on sequence novelty, preparation purity, and the presence of adjuvant-like contaminants. Compounded emideltide preparations sourced from non-GMP bulk drug substance suppliers carry the same endotoxin contamination and sequence-error risks that the FDA has cited for other compounded peptides. No compounding pharmacy-level purity standard for emideltide has been established or validated.
Long-term safety data are absent entirely. The longest follow-up period in any published human study is approximately four weeks. The consequences of repeated or chronic emideltide administration — including effects on endogenous DSIP production, HPA axis regulation, opioid receptor sensitivity, and immune function — have not been characterised in humans. This is a fundamental safety unknown that cannot be addressed by extrapolation from short-term open-label series.
What Does the Evidence Gap Mean for Practitioners Considering Emideltide Protocols in 2026?
The absence of controlled human evidence across all three proposed indications means any emideltide protocol in 2026 operates entirely outside an evidence-supported framework. Practitioners must communicate this clearly: the compound has no approved indication, no validated dosing protocol, no human pharmacokinetic characterisation, and no controlled efficacy data in any human population studied to date.
| Indication | Best Available Human Evidence | Study Design | Key Methodological Gaps | Regulatory Status (2026) |
|---|---|---|---|---|
| Insomnia | Schoenenberger et al. (1984): 12-patient open series; Graf et al. (1985): 20-patient open series | Open-label, uncontrolled IV infusion | No placebo arm; no polysomnography; no blinding; expectation effects uncontrolled | No approved indication; no IND; 503A compounding eligibility not established |
| Narcolepsy | No dedicated clinical trial; scattered case reports in hypersomnia literature | Case reports only | No ICSD-3 diagnostic criteria applied; no orexin measurement; no validated sleepiness instruments | No approved indication; no IND; mechanistic rationale untested in orexin-deficient models |
| Opioid Use Disorder | Sudakov series (1989–1995); Kopytov et al. (1998): 28-patient uncontrolled series | Open-label, uncontrolled IV infusion with historical comparators | No randomisation; no allocation concealment; no blinding; non-validated outcome instruments; no PK data | No approved indication; no IND; 503A compounding eligibility not established |
Safety Considerations: What Practitioners Must Communicate to Patients About Emideltide in 2026
Practitioners discussing emideltide with patients in 2026 face a mandatory informed-consent obligation spanning four domains: the complete absence of controlled human efficacy data, the uncharacterised pharmacokinetic profile, the unknown immunogenicity and long-term safety of injectable preparations, and the lack of any regulatory-approved compounding pathway. Each gap represents a material risk requiring explicit patient disclosure.
The informed-consent discussion should explicitly address that emideltide's proposed benefits in insomnia, narcolepsy, and opioid use disorder rest on open-label series with 12 to 40 participants, conducted without placebo controls, blinding, or validated outcome instruments. These studies cannot establish that observed effects exceed placebo response — a particularly important caveat for sleep and withdrawal indications, where placebo effects are well-documented and clinically significant.
For patients with opioid use disorder, practitioners must weigh emideltide's uncharacterised evidence base against the established efficacy and safety profiles of approved medications — specifically buprenorphine, methadone, and naltrexone — which have been evaluated in large randomised controlled trials and carry FDA approval. No comparative effectiveness claim for emideltide versus approved agents can be made.
Compounded emideltide preparations carry the manufacturing quality risks common to all non-GMP peptide injectables: endotoxin contamination, sequence errors from synthesis, oxidised residues acting as neoantigens, and variable potency between batches. Practitioners sourcing compounded emideltide should request certificates of analysis with validated endotoxin testing and sequence confirmation by mass spectrometry — and should document that this information was reviewed and disclosed to the patient.
For the broader regulatory context on how the FDA evaluates peptide compounding eligibility when human data are absent, see What Did the FDA's Pharmacy Compounding Advisory Committee Recommend in July 2026 About BPC-157, KPV, TB-500, and MOTS-c? For the mechanistic evidence base underlying DSIP's sleep-regulatory role, see How Does Delta Sleep-Inducing Peptide Regulate Sleep Architecture — What Does the Mechanistic Evidence Show in 2026? Does the FDA's 2026 Compounding Crackdown on BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax Reflect Clinical Evidence or Regulatory Process? Which Peptides Could Exit the FDA's Compounding Restriction List After the July 2026 Advisory Vote? What Does the 2026 Clinical Evidence Actually Show for BPC-157 in Shoulder Rotator Cuff Tears?